ID: ALA5187585

Max Phase: Preclinical

Molecular Formula: C18H18F6OSi

Molecular Weight: 392.42

Representations

Canonical SMILES:  C[Si](C)(Cc1ccccc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1

Standard InChI:  InChI=1S/C18H18F6OSi/c1-26(2,12-13-6-4-3-5-7-13)15-10-8-14(9-11-15)16(25,17(19,20)21)18(22,23)24/h3-11,25H,12H2,1-2H3

Standard InChI Key:  UHDBFZNWFWMGJD-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 392.42

Molecular Weight (Monoisotopic): 392.1031

AlogP:

#Rotatable Bonds:

Polar Surface Area:

Molecular Species:

HBA:

HBD:

#RO5 Violations:

HBA (Lipinski):

HBD (Lipinski):

#RO5 Violations (Lipinski):

CX Acidic pKa:

CX Basic pKa:

CX LogP:

CX LogD:

Aromatic Rings:

Heavy Atoms:

QED Weighted:

Np Likeness Score:

References

1. Namba N, Noguchi-Yachide T, Matsumoto Y, Hashimoto Y, Fujii S..  (2022)  Design, synthesis and structure-activity relationship of 4-(1,1,1,3,3,3-hexafluoro-2-hydroxyisoprop-2-yl)phenylsilane derivatives as liver X receptor agonists.,  66  [PMID:35576658] [10.1016/j.bmc.2022.116792]

Source

Source(1):

• Scientific Literature